1. Mahida K, Jagtap SR.
   Letter to the editor regarding "Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy".
   AIDS 2026;40:1050-1051.
   


2. Calcagno A, Strano M, Lolatto R, Vercesi R, et al.
   Plasma central nervous system biomarkers in heavily treatment-experienced people with HIV in the PRESTIGIO registry.
   AIDS 2026;40:1045-1049.
   


3. Ahuja S, Maurer T, Sales C, Chemtai L, et al.
   Implementation of teledermatology to identify and expedite care for Kaposi sarcoma.
   AIDS 2026;40:1043-1045.
   


4. Ryscavage P, Knable C, Taylor G.
   Low measles seroprotection among adults with perinatally acquired HIV.
   AIDS 2026;40:1041-1043.
   


5. Orozco F, Benham C, Xiang C, Vemulapalli A, et al.
   Leveraging HIV/AIDS infrastructure for sustainable healthcare services in sub-Saharan Africa.
   AIDS 2026;40:1034-1038.
   


6. Jarvis JN, Sivile S.
   Advanced HIV disease.
   AIDS 2026;40:1031-1033.
   


7. Aliyu AT, Dakum PS, Ryscavage P, Blanco N, et al.
   High blood pressure and associated metabolic disorders among young adults with and without perinatal HIV.
   AIDS 2026.
   


8. Harris DA, Germano Toledo R, Hacker M, Wamakima B, et al.
   Persistent or recurrent cervical dysplasia in women living with HIV after treatment for high-grade dysplasia in Botswana.
   AIDS 2026.
   


9. Mcfarlane WJ, Flemming JA, Martinez-Cajas JL, Peng Y, et al.
   Liver disease risk attributable to HCV, HIV, and HCV-HIV coinfection: an interaction analysis.
   AIDS 2026.
   


10. Nicholls EJ, Bicarregui P, Brewster A, Ghosh I, et al.
    A systematic review of qualitative research on HIV and food insecurity in high-income countries.
    AIDS 2026.
    


11. Liang W, Zhang L, Wang B, Ben H, et al.
    Exposure to size-specific particulate matter accelerates DNA methylation aging in people living with HIV.
    AIDS 2026.
    


12. Coghill AE, Bender Ignacio R.
    Further unraveling the association between HIV, immune suppression, and cancer survival.
    Clin Infect Dis 2026.
    


13. Haas CB, Shiels MS, Luo Q, Pfeiffer RM, et al.
    Markers of immune function and survival among cancer patients with HIV in the United States: a population-based registry linkage study.
    Clin Infect Dis 2026.
    


14. Feser M, Maphosa T, Shroufi A, Rangaraj A, et al.
    Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi.
    Clin Infect Dis 2026.
    


15. Behuhuma N, Gasa G, Derache A, Nhlapo B, et al.
    Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa.
    Clin Infect Dis 2026.
    


16. Lee TH, Bhattacharya D, Kim HN.
    Don't Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for Treatment and Prevention of HIV.
    Clin Infect Dis 2026.
    


17. Weld ED, Scott RK.
    Long-Acting Antiretroviral Therapy to Treat Advanced Human Immunodeficiency Virus in Pregnancy: Let Not Delayed Detection Be the Enemy of the Good.
    Clin Infect Dis 2026.
    


18. Saltini P, Cozzi-Lepri A, Bozzi G, Tavelli A, et al.
    Pre-ART platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio and the risk of non-AIDS-events, AIDS-events and mortality in people with HIV.
    J Acquir Immune Defic Syndr 2026.
    


19. Willkens M, Issarow B, Kisigo GA, Kabakama S, et al.
    Sustainability of the Effects of Linkage Case Management on Posthospitalization HIV Outcomes: The Daraja Randomized Clinical Trial.
    J Acquir Immune Defic Syndr 2026.
    


20. Castellano C, Moran CA, Nguyen MT, Ramesh V, et al.
    Incidence and Risk Factors for Non-AIDS Comorbidities Following COVID-19 in People Living with HIV in Atlanta, Georgia.
    J Acquir Immune Defic Syndr 2026.
    


21. Wang H, Jonas KJ, van de Vijver D.
    Epidemiological impact of prioritising long-acting injectable cabotegravir to MSM with low PrEP use adherence in the Netherlands: A mathematical modelling study.
    J Acquir Immune Defic Syndr 2026.
    


22. Diamond TL, Grandhi A, Fuszard M, Xu Y, et al.
    Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.
    J Infect Dis 2026.
    


23. Xue K, Shi Y, Gan Y, Zhang R, et al.
    Altered Diffusion Tensor Image Analysis Along the Perivascular Space in People Living with HIV: Association with Cognition and Diagnostic Utility for Asymptomatic Neurocognitive Impairment.
    J Infect Dis 2026.
    


24. Zheng ZM, Majerciak V.
    ORF57/MTA in KSHV Biology and Pathogenesis: Update From 2015.
    J Med Virol 2026;98:e70979.
    


25. Figueroa Acosta DM, Valencia TR, Li H, Chen BK, et al.
    Endocytic motif on HIV-1 Env regulates cleavage status and antibody neutralization of cell-free and cell-to-cell infection.
    J Virol 2026.
    

Display articles in

• Abstract format